NASDAQ · Biotechnology

Galectin Therapeutics Inc. (GALT) Stock

$3.33 -4.18% NASDAQ: GALT Healthcare

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers.

Valuation

MetricValue
Price$3.33
Market Cap$218.97M
P/E Ratio-8.53
P/B Ratio-1.75
P/S Ratio0.00
EPS (TTM)$-0.48
52-Week High$7.13
52-Week Low$2.03
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE21.05%
ROA-166.58%
ROCE-192.44%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-1.04
Current Ratio2.38

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-30.0M$-38.0M$-38.0M$-42.0M$-20.0M
Net Profit$-31.0M$-39.0M$-41.0M$-47.0M$-31.0M
EPS$-0.52$-0.65$-0.74$-0.76$-0.48
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$42.0M$21.0M$28.0M$17.0M$20.0M
Total Liabilities$39.0M$53.0M$88.0M$121.0M$146.0M
Cash$40.0M$19.0M$26.0M$15.0M$18.0M
Borrowings$29.0M$40.0M$72.0M$106.0M$134.0M

Latest News

GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH Zacks · Jun 24, 2026 GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial Stocktwits · Jun 23, 2026 Galectin Therapeutics Says FDA Alignment Reached on Phase 3 Belapectin Trial MT Newswires · Jun 23, 2026 Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension GlobeNewswire · Jun 23, 2026 Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis GlobeNewswire · May 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-24.0M$-31.0M$-33.0M$-42.0M$-24.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$10.0M$0$0
Net Cash Flow$13.0M$-21.0M$7.0M$-11.0M$3.0M
Free Cash Flow$-24.0M$-31.0M$-33.0M$-42.0M$-24.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.25
EV / EBITDA-18.48
FCF Yield-10.96%
Quick Ratio2.38
Interest Coverage-2.86
Return 1Y22.34%
Return 3Y116.98%
Return 5Y78.95%

Ownership

Insiders Held29.09%
Institutions Held21.17%
Institutions Float Held29.86%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC1,966,5422026-03-31
Marshall Wace LLP1,219,9122026-03-31
Osaic Holdings Inc.1,122,6702026-03-31
Blackrock Inc.799,2372026-03-31
Millennium Management Llc798,4342026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALT $3.03 -1.30% -2.31 $267.42M 0.00%
AURA $7.06 -1.40% -4.35 $453.25M 0.00%
DMAC $6.65 -1.27% -8.09 $358.56M 0.00%
DRTS $11.59 -5.08% -18.73 $1.05B 0.00%
DSGN $13.57 +2.80% -11.56 $847.54M 0.00%

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.

Galectin Therapeutics Inc. is led by CEO Joel Lewis, employs 15 people, headquartered in US, publicly traded since 2002.

Galectin Therapeutics Inc. (GALT) stock trades at $3.33 with a market capitalization of $218.97M. The stock is valued at a price-to-earnings (P/E) ratio of -8.53, price-to-book of -1.75, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.03 and $7.13, and currently trades 53.3% below its 52-week high.

On profitability, Galectin Therapeutics Inc. generates a return on equity (ROE) of 21.05% — well above the market average, a sign of a high-quality business, return on capital employed of -192.44%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: galectintherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides